King Altace sNDA Submitted For Five Indications; 4th Quarter Sales Grew 46%
Executive Summary
King submitted an Altace (ramipril) sNDA Jan. 18 for the significant reduction of mortality, myocardial infarction, stroke, revascularization procedures and heart failure in patients at risk for such events.